YUCAIPA, Calif., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading manufacturer of respiratory medical devices, recently announced today that the company was granted approval of the Stage-I audit conducted by BSI America, Inc. on February 5, 2010.
On February 5, 2010 the company was audited by Mr. Brian Nguyen, one of the certified auditors with BSI America, Inc. According to Mr. Nguyen, Ingen's management system documentation meets the requirements of the ISO 13485:2003, the MDD 93/42/EEC Annex V (M5), and the CMDR. The internal audits and management review processes are being planned and performed. Based on the objective evidences noted from the areas assessed during this Stage-I audit, it is recommended that Ingen proceed to the final Stage-II audit. There were no outstanding non-conformities to review from previous assessments. No new non-conformities were identified during the assessment.
Ingen Technologies is strongly committed to the success of this company and continues driving forward in a direction that is within the best interest of its shareholders. The company has pending back-orders for export sales to China, Japan, Canada, Europe and Australia. Ingen has seen an increase in the value with its intellectual property, research & development, new medical product lines, inventory and other assets, while revenues show a steady incline. ISO Certification is expected to result in a large revenue jump of the company's respiratory product lines.
http://www.emergogroup.com/services-by-region/usa
About Ingen:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.